$29.11
1.29% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US19459J1043
Symbol
COLL

Collegium Pharmaceutical, Inc. Stock price

$29.11
-1.60 5.21% 1M
-3.33 10.27% 6M
-1.67 5.43% YTD
-1.67 5.43% 1Y
+9.21 46.28% 3Y
+8.14 38.82% 5Y
+16.82 136.86% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.38 1.29%
ISIN
US19459J1043
Symbol
COLL
Sector
Industry

Key metrics

Market capitalization $938.80m
Enterprise Value $1.79b
P/E (TTM) P/E ratio 12.56
EV/FCF (TTM) EV/FCF 9.29
EV/Sales (TTM) EV/Sales 2.98
P/S ratio (TTM) P/S ratio 1.57
P/B ratio (TTM) P/B ratio 4.00
Revenue growth (TTM) Revenue growth 9.62%
Revenue (TTM) Revenue $599.25m
EBIT (operating result TTM) EBIT $213.36m
Free Cash Flow (TTM) Free Cash Flow $192.43m
Cash position $144.96m
EPS (TTM) EPS $2.32
P/E forward 15.65
P/S forward 1.49
EV/Sales forward 2.84
Short interest 23.48%
Show more

Is Collegium Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Collegium Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

3x Buy
60%
2x Hold
40%

Analyst Opinions

5 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

Buy
60%
Hold
40%

Financial data from Collegium Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
599 599
10% 10%
100%
- Direct Costs 226 226
13% 13%
38%
374 374
31% 31%
62%
- Selling and Administrative Expenses 12 12
209% 209%
2%
- Research and Development Expense - -
-
-
361 361
28% 28%
60%
- Depreciation and Amortization 148 148
2% 2%
25%
EBIT (Operating Income) EBIT 213 213
64% 64%
36%
Net Profit 89 89
882% 882%
15%

In millions USD.

Don't miss a Thing! We will send you all news about Collegium Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Collegium Pharmaceutical, Inc. Stock News

Positive
Seeking Alpha
about one month ago
Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of Jornay PM expands COLL's portfolio into neurology, tapping into the rapidly growing ADHD market, which is projected to reach $30.6 billion by 2032. Collegium reported strong Q3 2024 results, with 17...
Neutral
GlobeNewsWire
about one month ago
MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children.
Neutral
Seeking Alpha
about 2 months ago
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Sec...
More Collegium Pharmaceutical, Inc. News

Company Profile

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Head office United States
CEO Vikram Karnani
Employees 197
Founded 2002
Website www.collegiumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today